Biogen Idec Inc., the Weston biotechnology company known for its drugs to treat multiple sclerosis drugs, is seeking US regulatory approval for a long-lasting treatment for hemophilia A, a rare inherited disorder that impairs blood clotting.
Current treatments can require a patient to get three or four injections a week. Biogen Idec’s hope is that a patient would need one or two injections per week.
If approved, the treatment would be the first major advance for hemophilia A patients in more than two decades, the company said.
In a press release, the company said it is seeking Food and Drug Administration approval to the market recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.